Extracorporeal cytokine adsorption as therapeutic option for immune effector cell-associated neurotoxicity syndrome
With the rising number of patients receiving chimeric antigen receptor T-cells, the treatment of this therapy's complications is of growing concern to intensivists and neurologists. We used extracorporeal cytokine adsorption as an add-on therapy in a patient suffering from immune effector cell-associated neurotoxicity syndrome. Interleukin-6 level, which as a readily available parameter is generally used to evaluate course of disease, was rapidly reduced using this method. The patient made a full recovery and is still in hematological remission.
Authors
- Sascha David (ORCID: https://orcid.org/0000-0002-8231-0461)
- Dominik Schneidawind (ORCID: https://orcid.org/0000-0002-2672-431X)
- Emanuel Rom
- Giovanna Schweiger (ORCID: https://orcid.org/0000-0002-9284-896X)
- A. Bühlmann
Institutions
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Neurological Sciences
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1007/s10072-024-07812-1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universität Zürich